Düsseldorf, Germany – December 23rd, 2025 – LenioBio GmbH, a pioneer in cell-free protein expression technology, today announced that Dr. Desmond Schofield has joined the company as Head of Business Development.
Dr. Schofield brings extensive experience across protein production, process development, and commercial leadership within the life sciences sector. Most recently, he served as Chief Business Officer at evitria AG, where he progressed from Director of Business Development and played a key role in expanding the company’s commercial operations and global presence.
Prior to evitria, Dr. Schofield held commercial development roles at Sartorius, following earlier experience as a process development scientist. He has a doctorate in Biochemical Engineering from University College London, providing a strong technical foundation that underpins his commercial expertise.
Throughout his career, Dr. Schofield has worked closely with discovery and preclinical teams and has seen first-hand the growing impact of AI-driven discovery workflows and the increasing demand for non-standard and highly complex biologics. LenioBio’seukaryotic cell-free protein expression platform is well–positioned to meet these emerging needs by enabling rapid, flexible access to challenging proteins.
“I’ve seen first-hand the explosion in AI-led discovery work and high complexity molecules, and LenioBio’s eukaryotic cell-free expression platform is your perfect implementation partner: almost-impossible-to-express proteins are delivered in incredible timelines,” said Dr. Schofield. “Looking forward to working with the LenioBioteam and collaborators to expand the potential of cell-free protein expression.”
Dr. Schofield’s appointment further strengthens LenioBio’s leadership team as the company continues to support Biopharma teams developing the next generation of therapeutics.
About LenioBio
LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins beyond the limits of living cells. Founded in Germany in 2016, LenioBio is headquartered in Düsseldorf with R&D and manufacturing facilities in Aachen.
For more information, visit www.leniobio.com and follow us on LinkedIn.